Back to top

Buy Rating Affirmed for Cytokinetics Amid Strong Aficamten Trial Results

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report), with a price ta...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cytokinetics, Incorporated (CYTK)